SCHEMBL11945076

SCHEMBL11945076

CCOCCOc1c(N2CCN(S(=O)(=O)Cc3ccccc3)CC2)cnn(-c2ccccn2)c1=O

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.45
▸ MAPT P10636 2/20 0.45
▸ KDM4E B2RXH2 2/20 0.45
▸ HSD17B10 Q99714 2/20 0.42
▸ MEN1 O00255 3/20 0.41
▸ KMT2A Q03164 3/20 0.41
▸ HSD11B1 P28845 1/20 0.40
▸ GAA P10253 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ CA12 O43570 1/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ CA9 Q16790 1/20 0.39
▸ DCTPP1 Q9H773 1/20 0.37
▸ SMO Q99835 1/20 0.36
▸ PKM P14618 1/20 0.36
▸ NPSR1 Q6W5P4 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943902 0.91 ALDH1A1 (0.46) ALDH1A1MAPTKDM4EHSD17B10MEN1
SCHEMBL11943544 0.90 MAPT (0.56) ALDH1A1MAPTHSD17B10KMT2AGAA
SCHEMBL11943957 0.86 HSD17B10 (0.46) ALDH1A1MAPTKDM4EHSD17B10HSD11B1
SCHEMBL11943954 0.86 MEN1 (0.42) ALDH1A1MAPTKDM4EHSD17B10MEN1
SCHEMBL11943949 0.86 MAPT (0.52) ALDH1A1MAPTHSD17B10GAATSHR
SCHEMBL11944009 0.85 MAPT (0.47) ALDH1A1MAPTHSD17B10HSD11B1GAA
SCHEMBL11943956 0.84 MAPT (0.49) ALDH1A1MAPTHSD17B10HSD11B1GAA
SCHEMBL11945108 0.84 MAPT (0.49) ALDH1A1MAPTKMT2AGAATSHR
SCHEMBL11943951 0.84 MAPT (0.53) ALDH1A1MAPTKDM4EGAATSHR
SCHEMBL11945010 0.84 MAPT (0.52) ALDH1A1MAPTKDM4EHSD17B10KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA ALDH1A1 2437/4885MAPT 2295/4885KDM4E 1548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback